| Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT P Dubreuil, S Letard, M Ciufolini, L Gros, M Humbert, N Castéran, L Borge, ... PloS one 4 (9), e7258, 2009 | 456 | 2009 |
| Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells A Chaix, S Lopez, E Voisset, L Gros, P Dubreuil, P De Sepulveda Journal of Biological Chemistry 286 (8), 5956-5966, 2011 | 74 | 2011 |
| The tyrosine kinase FES is an essential effector of KITD816V proliferation signal E Voisset, S Lopez, P Dubreuil, P De Sepulveda Blood, The Journal of the American Society of Hematology 110 (7), 2593-2599, 2007 | 61 | 2007 |
| FES kinases are required for oncogenic FLT3 signaling E Voisset, S Lopez, A Chaix, C Georges, K Hanssens, T Prebet, ... Leukemia 24 (4), 721-728, 2010 | 44 | 2010 |
| Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice E Voisset, E Moravcsik, EW Stratford, A Jaye, CJ Palgrave, RK Hills, ... Blood, The Journal of the American Society of Hematology 131 (6), 636-648, 2018 | 43 | 2018 |
| The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia JV Jovanovic, MC Chillon, C Vincent-Fabert, R Dillon, E Voisset, ... Leukemia 31 (3), 747-751, 2017 | 33 | 2017 |
| KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570 A Chaix, ML Arcangeli, S Lopez, E Voisset, Y Yang, M Vita, S Letard, ... Oncogene 33 (7), 872-881, 2014 | 32 | 2014 |
| An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia S Lopez, E Voisset, JC Tisserand, C Mosca, T Prebet, D Santamaria, ... Oncotarget 7 (32), 51163, 2016 | 26 | 2016 |
| SRC-family kinases in acute myeloid leukaemia and mastocytosis E Voisset, F Brenet, S Lopez, P de Sepulveda Cancers 12 (7), 1996, 2020 | 19 | 2020 |
| The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability W Grey, A Ivey, TA Milne, T Haferlach, D Grimwade, F Uhlmann, E Voisset, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1865 (1), 105-116, 2018 | 17 | 2018 |
| From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia M Saez-Ayala, L Hoffer, S Abel, K Ben Yaala, B Sicard, GP Andrieu, ... Nature Communications 14 (1), 3079, 2023 | 12 | 2023 |
| p38α negatively regulates survival and malignant selection of transformed bronchioalveolar stem cells E Voisset, F Oeztuerk-Winder, EJ Ruiz, JJ Ventura PLoS One 8 (11), e78911, 2013 | 10 | 2013 |
| FES kinase participates in KIT-ligand induced chemotaxis E Voisset, S Lopez, A Chaix, M Vita, C George, P Dubreuil, ... Biochemical and biophysical research communications 393 (1), 174-178, 2010 | 9 | 2010 |
| TET2 regulates immune tolerance in chronically activated mast cells R Rigo, R Chelbi, J Agopian, S Letard, A Griffon, H Ghamlouch, ... JCI insight 7 (7), 2022 | 4 | 2022 |
| Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance M Ozgencil, J Barwell, M Tischkowitz, L Izatt, I Kesterton, M Simpson, ... Plos one 16 (12), e0260852, 2021 | 2 | 2021 |
| Pml nuclear body disruption cooperates in APL pathogenesis, impacting DNA damage repair pathways E Voisset, E Moravcsik, EW Stratford, A Jaye, CJ Palgrave, RK Hills, ... Blood 128 (22), 742, 2016 | 2 | 2016 |
| The IRF2BP2-RARα fusion generated by a cryptic rearrangement transforms hematopoietic stem/progenitor cells and induces retinoid sensitive acute promyelocytic leukemia (APL) JV Jovanovic, MC Chillón, C Vincent-Fabert, R Dillon, E Voisset, ... Blood 124 (21), 2325, 2014 | 1 | 2014 |
| Disruption of pml nuclear bodies cooperates in the pathogenesis of acute promyelocytic leukemia E Moravcsik, M Joannides, E Voisset, EW Stratford, BB Zeisig, J Morris, ... Blood 122 (21), 3721, 2013 | 1 | 2013 |
| The Recurrent Liver MAN2A1-FER Oncoprotein Lacks Kinase Activity: Implications for the Use of Tyrosine Kinase Inhibitors M Desaunay, E Voisset, S Letard, P Roche, P De Sepulveda Cellular and Molecular Gastroenterology and Hepatology 17 (4), 667-669, 2024 | | 2024 |
| 01. Hématopoïèse et oncogenèse E Voisset, E Lecocq, L Brault, M Desaunay, P Dubreuil, P De Sepulveda Hématologie 28 (1), 4-6, 2022 | | 2022 |
